JW Jungwo Pharmaceutical Holds Support Event for 'World Hemophilia Day'

[Asia Economy Reporter Lee Gwan-joo] JW Pharmaceutical announced on the 15th that it will conduct the ‘BRAVO Campaign’ to raise awareness of hemophilia and send support messages to patients in celebration of ‘World Hemophilia Day’ on the 17th.

Marking its 32nd year, ‘World Hemophilia Day’ was established in 1989 by the World Federation of Hemophilia (WFH) to increase social awareness of hemophilia and bleeding disorders.

The ‘BRAVO Campaign’ is JW Pharmaceutical’s social contribution program that raises social interest in rare diseases, provides patients with necessary treatment information, and helps alleviate their economic burdens.

JW Pharmaceutical will first run a hemophilia patient support event on the JW Group’s official YouTube channel ‘Healthpedia’ until the 29th of this month. Among participants who watch the ‘Curious About Hemophilia’ episode posted on Healthpedia and leave a supportive comment, 50 will be selected by lottery to receive the JW Group’s skincare brand ‘Ringsel Total Set,’ and 100 will receive the health supplement ‘Mycode Multi Vitamin & Mineral.’

The ‘Curious About Hemophilia’ episode is a video content in which Professor Yoo Cheol-joo of the Pediatric Hematology-Oncology Department at Sinchon Severance Yonsei Cancer Hospital explains under the theme ‘Hemophilia, a rare disease where bleeding doesn’t stop, with invisible bleeding being more frightening.’

In addition, JW Pharmaceutical will carry out activities to raise awareness of hemophilia among its employees. The story of translator Park Hyun-mook, who suffers from type A hemophilia, titled ‘I Don’t Want to Become an Adult Who Only Hurts,’ has been registered as the April book on ‘JW Learning Cloud,’ JW Group’s employee learning platform.

JW Pharmaceutical plans to continue activities to improve awareness of rare diseases. A JW Pharmaceutical official said, “JW Pharmaceutical is leading efforts to improve the quality of life for domestic hemophilia patients by developing and supplying the subcutaneous injection drug ‘Hemlibra.’ We will continue to carry out various activities to raise social interest in rare diseases and support overcoming these conditions.”